Compare Novavax Inc (NVAX) vs Upstart Holdings Inc (UPST) Price & Performance

Novavax (NVAX) trades at $10.19, showing modest daily movement with a -0.29% decline. The stock maintains a bullish technical signal with strong moving average support. Recent quarterly earnings have consistently beaten expectations, though the company faces profitability challenges with a -59.87% net income margin. Positive developments include regulatory approvals for its updated COVID-19 vaccine and progress in the Sanofi partnership, driving investor optimism.

The outlook remains mixed with strong analyst support (74% buy ratings) but significant financial risks. Investment opportunity lies in the company's partnership strategy and Matrix-M adjuvant platform, while risks include cash flow challenges and competitive vaccine market pressures. The stock's low P/E ratio of 3.14 suggests potential undervaluation if operational improvements continue.

Upstart Holdings (UPST) trades at $26.98, down 3.81% on the day, reflecting bearish technical momentum and recent earnings misses. The stock shows oversold conditions with an RSI of 18.98, while fundamentals indicate a turnaround with 2025 net income of $53.60M on $1.02B revenue, marking its first annual profit. Analyst sentiment is mixed with a 45.46% buy rating and $47.20 consensus target, but insider selling and weak cash flow from operations pose concerns.

The outlook hinges on execution in personal loan growth and AI lending efficiency, but risks include high debt-to-asset ratio of 61.48% and macroeconomic sensitivity. Near-term resistance at $28 challenges upside, while support at $26 may stabilize declines if earnings improve in Q3 2026.